Showing posts with label mayo clinic. Show all posts
Showing posts with label mayo clinic. Show all posts

Sunday, January 20, 2019

Hippocampal-Sparing Alzheimer's Goes Dangerously Misdiagnosed

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Mayo Clinic

Hundreds of thousands of people with Hippocampal-Sparing Alzheimer's go misdiagnosed. With a correct diagnosis, existing medicines can do more. Learn about the diagnosis and treatment for this common type of dementia. 




JACKSONVILLE, Fla. — Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer’s disease (AD) that they say is neither well recognized nor treated appropriately.


 The variant, called hippocampal sparing AD (short for hippocampal sparing Alzheimer's disease), made up 11 percent of the 1,821 Alzheimer's-confirmed brains examined by Mayo Clinic researchers — suggesting this subtype is relatively widespread in the general population. The Alzheimer’s Association estimates that 5.2 million Americans are living with Alzheimer’s disease (AD). With nearly half of hippocampal sparing AD patients being misdiagnosed, this could mean that well over 600,000 Americans make up this AD variant, researchers say.

Unique Symptoms

In an oral presentation at the annual meeting of the American Academy of Neurology in Philadelphia, scientists say hippocampal sparing AD often produces symptoms that are substantially different from the most commonly known form of AD, which affects the hippocampus, the center of memory.

The patients, mostly male, are afflicted at a much younger age, and their symptoms can be bizarre — behavioral problems such as frequent and sometimes profane angry outbursts, feelings that their limbs do not belong to them and are controlled by an “alien” unidentifiable force, or visual disturbances in the absence of eye problems, researchers say.

They also decline at a much faster rate than do patients with the most common form of AD.

“Many of these patients, however, have memories that are near normal, so clinicians often misdiagnose them with a variety of conditions that do not match the underlying neuropathology,” says the study’s lead author, Melissa Murray, Ph.D., an assistant professor of neuroscience at Mayo Clinic in Florida.

Misdiagnosis & Consequences

Many of these patients are misdiagnosed with frontotemporal dementia, a disorder characterized by changes in personality and social behavior, or corticobasal syndrome, characterized by movement disorders and cognitive dysfunction. Language dysfunction is also more common in hippocampal sparing AD, although patients do not have vocal or hearing deficits.

“What is tragic is that these patients are commonly misdiagnosed and we have new evidence that suggests drugs now on the market for AD could work best in these hippocampal sparing patients — possibly better than they work in the common form of the disease,” Dr. Murray says.

The researchers benefit greatly from one of the largest brain banks in the country — more than 6,500 brain donations — as well as a collaborative environment between neuroscience research and neurology at Mayo Clinic, she says.

Both hallmark proteins of AD — amyloid beta (Aβ), which forms Aβ plaques, and tau, which produces tangles — are found across all subtypes of AD, including hippocampal sparing AD. The researchers developed a mathematical algorithm to classify AD subtypes using tangle counts. “What is fascinating is that all the AD patient subtypes had the same amount of amyloid, but for some reason tau tangles were found in strategic cortical regions disproportionate to the hippocampus.”

In these patients, tau preferentially damages and eventually destroys neurons in parts of the brain involved in behavior, motor awareness and recognition, as well as use of speech and vision, Dr. Murray says.

She says she hopes this research, the second high-profile Mayo study to highlight hippocampal sparing AD, will “open the minds” of clinicians who are trying to diagnose dementia, helping them understand that loss of memory is not present in every AD patient.

“Our studies support the notion that dementia related to AD does not necessarily equate to a loss of memory, and points to the need for more research in amyloid and tau imaging biomarkers to help clinicians accurately diagnose AD — regardless of subtype,” Dr. Murray says.

About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or newsnetwork.mayoclinic.org/.

Tuesday, April 3, 2018

Some with Alzheimer's are misdiagnosed

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

MAYO CLINIC DIAGNOSIS VIDEO + ARTICLE: 

Hundreds of thousands of people with Hippocampal-Sparing Alzheimer's go misdiagnosed. With a correct diagnosis, existing medicines can do more. Learn about the diagnosis and treatment for this common type of dementia. 




JACKSONVILLE, Fla. — Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer’s disease (AD) that they say is neither well recognized nor treated appropriately. 

Continued below video...


The variant, called hippocampal sparing AD (short for hippocampal sparing Alzheimer's disease), made up 11 percent of the 1,821 Alzheimer's-confirmed brains examined by Mayo Clinic researchers — suggesting this subtype is relatively widespread in the general population. The Alzheimer’s Association estimates that 5.2 million Americans are living with Alzheimer’s disease (AD). With nearly half of hippocampal sparing AD patients being misdiagnosed, this could mean that well over 600,000 Americans make up this AD variant, researchers say.

Unique Symptoms

In an oral presentation at the annual meeting of the American Academy of Neurology in Philadelphia, scientists say hippocampal sparing AD often produces symptoms that are substantially different from the most commonly known form of AD, which affects the hippocampus, the center of memory.

The patients, mostly male, are afflicted at a much younger age, and their symptoms can be bizarre — behavioral problems such as frequent and sometimes profane angry outbursts, feelings that their limbs do not belong to them and are controlled by an “alien” unidentifiable force, or visual disturbances in the absence of eye problems, researchers say.

They also decline at a much faster rate than do patients with the most common form of AD.

“Many of these patients, however, have memories that are near normal, so clinicians often misdiagnose them with a variety of conditions that do not match the underlying neuropathology,” says the study’s lead author, Melissa Murray, Ph.D., an assistant professor of neuroscience at Mayo Clinic in Florida.

Misdiagnosis & Consequences

Many of these patients are misdiagnosed with frontotemporal dementia, a disorder characterized by changes in personality and social behavior, or corticobasal syndrome, characterized by movement disorders and cognitive dysfunction. Language dysfunction is also more common in hippocampal sparing AD, although patients do not have vocal or hearing deficits.

“What is tragic is that these patients are commonly misdiagnosed and we have new evidence that suggests drugs now on the market for AD could work best in these hippocampal sparing patients — possibly better than they work in the common form of the disease,” Dr. Murray says.

The researchers benefit greatly from one of the largest brain banks in the country — more than 6,500 brain donations — as well as a collaborative environment between neuroscience research and neurology at Mayo Clinic, she says.

Both hallmark proteins of AD — amyloid beta (Aβ), which forms Aβ plaques, and tau, which produces tangles — are found across all subtypes of AD, including hippocampal sparing AD. The researchers developed a mathematical algorithm to classify AD subtypes using tangle counts. “What is fascinating is that all the AD patient subtypes had the same amount of amyloid, but for some reason tau tangles were found in strategic cortical regions disproportionate to the hippocampus.”

In these patients, tau preferentially damages and eventually destroys neurons in parts of the brain involved in behavior, motor awareness and recognition, as well as use of speech and vision, Dr. Murray says.

She says she hopes this research, the second high-profile Mayo study to highlight hippocampal sparing AD, will “open the minds” of clinicians who are trying to diagnose dementia, helping them understand that loss of memory is not present in every AD patient.

“Our studies support the notion that dementia related to AD does not necessarily equate to a loss of memory, and points to the need for more research in amyloid and tau imaging biomarkers to help clinicians accurately diagnose AD — regardless of subtype,” Dr. Murray says.

Wednesday, September 6, 2017

Active mind keeps dementia at bay

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Find out about activities that help your mind push off Alzheimer's by as much as 8 years. 

  • American Academy of Neurology

  • The Mayo Clinic


  • MINNEAPOLIS – People who keep mentally and physically healthy in middle age may help stave off the symptoms of Alzheimer's disease, according to a study published in the online edition of Neurology®, the medical journal of the American Academy of Neurology. 

    Continued below video...


    The findings differed for people who are carriers of a gene linked to Alzheimer's, called APOE4, which affects about 20 percent of the population. Those with the gene who had at least 14 years of education and kept mentally active in middle age had lower levels of proteins, called amyloid plaques, that can build up in brain tissue and lead to Alzheimer's disease than those with the gene and a high level of education but who did not keep mentally active in middle age. Among the APOE4 high education individuals, the predicted amyloid levels in a 79-year-old who kept mentally active (67th percentile) would be the same as the predicted amyloid levels in a 74 year-old who did not (33rd percentile). 

    "Recent studies have shown conflicting results about the value of physical and mental activity related to the risk of developing Alzheimer's disease, and we noticed that levels of education differed in those studies," said study author Prashanthi Vemuri, PhD, of the Mayo Clinic in Rochester, Minn. "When we looked specifically at the level of lifetime learning, we found that carriers of the APOE4 gene who had higher education and continued to learn through middle age had fewer amyloid deposition on imaging when compared to those who did not continue with intellectual activity in middle age." 

    Vemuri said the overall findings for people who do not carry the gene should not discourage people from exercising and taking part in activities such as reading books and magazines, playing games and using computers. "There is substantial evidence that these activities help to delay the onset of memory and thinking problems," Vemuri said. "What we don't know is how this process works." 

    For the study, researchers evaluated 393 people without dementia who were part of the Mayo Clinic Study of Aging. Of those, 53 had mild cognitive impairment. All were 70 years of age or older. They were divided into two groups, those with more than 14 years of education and those with less. 

    Researchers then used MRI and PET scans to look for biomarkers of Alzheimer's disease and questionnaires to evaluate weekly intellectual and physical activity in middle age. 

    For the group as a whole, education, occupation and mental and physical activity in middle age appeared to have little to no effect on the rates of worsening amyloid plaques, brain glucose metabolism and brain volume. But for APOE4 carriers with high education and continued lifetime learning, there was less amyloid deposition in the brain than those with high education who did not continue to learn. 

    "It is possible those who did not continue intellectual activity in middle age did so because they had higher levels of amyloid plaques," said Vemuri. "While there are many limitations with this study, our findings show further study is needed and suggest that differing education levels in other recent studies may explain the conflicting results seen in the research literature." 


    REFERENCE:
    MORE INFORMATION:

    • The study was supported by the National Institutes of Health.
    • The American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

    Monday, May 22, 2017

    Hippocampal-Sparing Alzheimer's Goes Dangerously Misdiagnosed

    Caregivers, and healthcare professionals,here is some great information

    Here is a great 
    dementia resource for caregivers and healthcare professionals,

    Your residents will love the Amazon Kindle Fire

    Here is information on being the best 
    caregiver you can be


    Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

    Follow 
    alzheimersideas on twitter


    The Dementia Caregiver's Little Book of Hope [Kindle Edition

    Hundreds of thousands of people with Hippocampal-Sparing Alzheimer's go misdiagnosed. With a correct diagnosis, existing medicines can do more. Learn about the diagnosis and treatment for this common type of dementia. 



    JACKSONVILLE, Fla. — Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer’s disease (AD) that they say is neither well recognized nor treated appropriately. 

    The variant, called hippocampal sparing AD (short for hippocampal sparing Alzheimer's disease), made up 11 percent of the 1,821 Alzheimer's-confirmed brains examined by Mayo Clinic researchers — suggesting this subtype is relatively widespread in the general population. The Alzheimer’s Association estimates that 5.2 million Americans are living with Alzheimer’s disease (AD). With nearly half of hippocampal sparing AD patients being misdiagnosed, this could mean that well over 600,000 Americans make up this AD variant, researchers say.

    Unique Symptoms

    In an oral presentation at the annual meeting of the American Academy of Neurology in Philadelphia, scientists say hippocampal sparing AD often produces symptoms that are substantially different from the most commonly known form of AD, which affects the hippocampus, the center of memory.

    The patients, mostly male, are afflicted at a much younger age, and their symptoms can be bizarre — behavioral problems such as frequent and sometimes profane angry outbursts, feelings that their limbs do not belong to them and are controlled by an “alien” unidentifiable force, or visual disturbances in the absence of eye problems, researchers say.

    They also decline at a much faster rate than do patients with the most common form of AD.

    “Many of these patients, however, have memories that are near normal, so clinicians often misdiagnose them with a variety of conditions that do not match the underlying neuropathology,” says the study’s lead author, Melissa Murray, Ph.D., an assistant professor of neuroscience at Mayo Clinic in Florida.

    Misiagnosis & Consequences

    Many of these patients are misdiagnosed with frontotemporal dementia, a disorder characterized by changes in personality and social behavior, or corticobasal syndrome, characterized by movement disorders and cognitive dysfunction. Language dysfunction is also more common in hippocampal sparing AD, although patients do not have vocal or hearing deficits.

    “What is tragic is that these patients are commonly misdiagnosed and we have new evidence that suggests drugs now on the market for AD could work best in these hippocampal sparing patients — possibly better than they work in the common form of the disease,” Dr. Murray says.

    The researchers benefit greatly from one of the largest brain banks in the country — more than 6,500 brain donations — as well as a collaborative environment between neuroscience research and neurology at Mayo Clinic, she says.

    Both hallmark proteins of AD — amyloid beta (Aβ), which forms Aβ plaques, and tau, which produces tangles — are found across all subtypes of AD, including hippocampal sparing AD. The researchers developed a mathematical algorithm to classify AD subtypes using tangle counts. “What is fascinating is that all the AD patient subtypes had the same amount of amyloid, but for some reason tau tangles were found in strategic cortical regions disproportionate to the hippocampus.”

    In these patients, tau preferentially damages and eventually destroys neurons in parts of the brain involved in behavior, motor awareness and recognition, as well as use of speech and vision, Dr. Murray says.

    She says she hopes this research, the second high-profile Mayo study to highlight hippocampal sparing AD, will “open the minds” of clinicians who are trying to diagnose dementia, helping them understand that loss of memory is not present in every AD patient.

    “Our studies support the notion that dementia related to AD does not necessarily equate to a loss of memory, and points to the need for more research in amyloid and tau imaging biomarkers to help clinicians accurately diagnose AD — regardless of subtype,” Dr. Murray says.

    Thursday, October 25, 2012

    High-carb diets tend to raise Alzheimer's risk


    Caregivers, and healthcare professionals, here is some great information

    Here is a great dementia resource for caregivers and healthcare professionals,


    Your residents will love the Amazon Kindle Fire


    Here is information on being the best caregiver you can be


    Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


    Follow alzheimersideas on twitter

    The Dementia Caregiver's Little Book of Hope [Kindle Edition

    Big News Network


    Seniors gorging on a carb rich diet are four times more likely to develop mild cognitive impairment -- an early warning of Alzheimer's disease, shows a new research.
    The research from the prestigious Mayo Clinic in America has found that risks are similar with a diet high in sugar. On the other hand, proteins and fats appear to offer some protection -- people who consumed plenty of them are less likely to suffer cognitive decline.
    Not everyone with mild cognitive impairment (MCI) develops Alzheimer's disease, but many do, said Rosebud Roberts, professor of epidemiology at the Mayo Clinic, who led the study.
    High-carb diets may play a role in the development of beta amyloid plaques, proteins found in the brains of people with Alzheimer's, the Daily Mail reported.
    MCI is defined as memory loss apparent to the individual and those around them, but with an absence of other dementia symptoms such as changes in personality and mood.
    There are currently 800,000 people with dementia in Britain and 60,000 deaths a year are directly attributable to it, according to the Alzheimer's Society. It's estimated around six percent of us will develop MCI.
    Previous research suggested that 10-15 percent of people with MCI went on to develop dementia every year the research results were followed up.
    In community studies and clinical trials the rates are about half this level, but still represent a significantly increased level of risk.
    That's why it's so important to identify people with MCI, as they may be in the very early stages of the disease and more likely to benefit from early treatment in the future.
    Mayo Clinic research tracked 1,230 people aged between 70 to 89 years and asked them to provide information on what they ate the previous year. However, proteins and fats appear to offer some protection - those who consumed plenty of them were less likely to suffer cognitive decline.

    Monday, May 14, 2012

    Mitochondria Dysfunction Occurs Early in Alzheimer’s Disease Prior to Memory Loss, Amyloid Deposits

    Here is a great dementia resource for caregivers and healthcare professionals,


    You will love the Amazon Kindle Fire


    Here is information on being the best caregiver you can be


    Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two


    Follow Alzheimers1 on twitter

    Highlight health

    Walter  Jessen
    Mitochondria are specialized subunits inside a cell that produce the cell’s energy and regulate its metabolism. Research suggests that mitochondria may play a central role in neuronal cell survival because they regulate both energy metabolism and cell death pathways. Using genetic mouse models of Alzheimer’s disease, researchers from Mayo Clinic have found that mitochondria in the brain are dysfunctional early in the disease. The findings were recently published in the open access journal PLoS ONE.

    Using real time imaging, scientists examined mitochondria in live neurons from three different mouse models of Alzheimer’s disease. Each of the mouse models had a different gene mutation shown to cause familial, or early-onset, Alzheimer’s disease. To evaluate the the impact of a given mutation, mitochondrial motility, distribution, ultrastructure and function in neurons and brain tissue was examined early in mouse development until the age where mice began to display memory loss and amyloid deposits formed.

    Researchers used a mitochondria-specific dye and monitored axonal trafficking (i.e. motion along axons or nerve fibers). The investigators found that mitochondrial axonal trafficking is inhibited in embryonic neurons afflicted with Alzheimer’s disease, well before mice showed any memory loss or amyloid plaque formation.


    Indeed, inhibition of axonal trafficking was found to be a general defect that occurred in all three mouse models of Alzheimer’s disease and was not specific for mitochondria. Nevertheless, neurons with inhibited mitochondrial trafficking were found to be more susceptible to excitotoxic cell death, a pathological process wherein nerve cells are killed by excessive neurotransmitter stimulation.
    In the brains of all three mouse models of Alzheimer’s disease, mitochondria tended to lose their integrity and subsequently stopped functioning. Importantly, dysfunctional mitochondria were detected at the synapses of neurons involved in maintaining memory, suggesting a direct linkage with Alzheimer’s disease.


    The scientists also applied a method called metabolomics, which measures the chemical fingerprints of specific metabolic pathways in the cell such as sugars, lipids, nucleotides, amino acids and fatty acids. The approach takes a snapshot of what is happening in the body at a given time and at a hight level of detail, and provides insight into the cellular processes that underlie a disease. For this study, the metabolomic profiles showed changes in metabolites related to mitochondrial function and cellular energy metabolism, which further confirmed that altered mitochondrial energetics is fundamental to the disease process.
    The researchers identified a panel of metabolomic biomarkers. According to Eugenia Trushina, Ph.D., Mayo Clinic pharmacologist and senior investigator on the study [2]:


    We are not looking at the consequences of Alzheimer’s disease, but at very early events and molecular mechanisms that lead to the disease. We expect to validate metabolomic changes in humans with Alzheimer’s disease and to use these biomarkers to diagnose the disease before symptoms appear — which is the ideal time to start treatment.

    The researchers conclude by stating that Alzheimer’s disease can be viewed as a mitochondrial movement disorder with evolving energetic deficit represented by the panel of metabolomic biomarkers and that mitochondrial dysfunction is an underlying event in Alzheimer’s disease progression.
    References


    1.Trushina et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer’s disease. PLoS One. 2012;7(2):e32737. Epub 2012 Feb 29.



    2.Mitochondrial Dysfunction Present Early in Alzheimer’s, Before Memory Loss. Mayo Clinic News. 2012 Feb 29.

    Monday, November 2, 2009

    Health Matters: New Discoveries In The Fight Against Alzheimer's Disease

    Here is a great dementia resource for caregivers and healthcare professinals,

    Here is information on being the best caregiver you can be

    Here are more interesting dementia brain boosting activities

    WCTV

    Triston Sanders-Medical Anchor

    Scientists make a big step in the battle against Alzheimer's Disease.
    Doctors with the Mayo Clinic in Jacksonville, Florida managed to remove amyloid plaques from the brains of mice.

    Those plaques are a hallmark of the disease.
    Researchers found the plaques clear when they injected a protein called "IL6" to the mice's immune system.

    The finding's a surprise, because researchers thought the protein would have actually made the plaques worse.

    The hope now is to use these findings to develop a new treatment for people with the degenerative disease.

    The research appears in the "Faseb Journal," which The Federation Of American Societies For Experimental Biology publishes.

    Tuesday, October 27, 2009

    Dementia Linked to High Cholesterol

    Here is a great dementia resource for caregivers and healthcare professinals,

    Here is information on being the best caregiver you can be

    Here are more interesting dementia brain boosting activities

    EmpowHer

    According to the National Institutes of Health, dementia rarely begins before age 60, and the risk of developing dementia increases with age. Degenerative dementia, which is caused by Alzheimer's disease and vascular dementia, cannot be reversed. Other forms of dementia caused by brain tumors, metabolic causes, infections, low vitamin B12 levels, normal pressure hydrocephalus and thyroid conditions, on the other hand, can be treated.

    The Mayo Clinic describes dementia as “a group of symptoms affecting intellectual and social abilities severely enough to interfere with daily functioning,” rather than a specific disorder. Symptoms of dementia include changes in feeling or perception, altered sleep patterns, decreases in problem-solving skills and judgment, disorientation, learning problems, impaired recognition, language problems, short-term and long-term memory problems, motor system problems, hallucinations and delusions, confusion and....... read more of Dementia Linked to High Cholesterol
    Blog Flux Directory
    alzheimersideas - whereIstand.com

    Fitness is important in dementia prevention. Click below for more info